Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.

@article{McElroy2013InhaledBD,
  title={Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.},
  author={Mary C McElroy and Chris Kirton and Dan Gliddon and Ron K Wolff},
  journal={Inhalation toxicology},
  year={2013},
  volume={25 4},
  pages={
          219-32
        }
}
Biopharmaceuticals are complex molecules often manufactured from living systems and their specificity and novelty holds great promise for the treatment of chronic diseases for which there are currently no cures. The inhalation route of biopharmaceutical drug delivery is attractive because the large surface area of the lung, and close proximity of the alveolar and vascular systems, maximizes the potential for drug delivery to the lung and/or systemic circulation. In addition, costs of delivery… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 citations